Vivoryon Therapeutics N.V. (AMS:VVY)

Netherlands flag Netherlands · Delayed Price · Currency is EUR
1.642
+0.008 (0.49%)
Sep 5, 2025, 5:35 PM CET
0.49%
Market Cap42.87M
Revenue (ttm)n/a
Net Income (ttm)-12.48M
Shares Out26.23M
EPS (ttm)-0.48
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume62,915
Average Volume88,932
Open1.630
Previous Close1.634
Day's Range1.586 - 1.650
52-Week Range1.370 - 3.000
Beta1.96
RSI59.11
Earnings DateSep 9, 2025

About Vivoryon Therapeutics

Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1997
Employees 14
Stock Exchange Euronext Amsterdam
Ticker Symbol VVY
Full Company Profile

Financial Performance

Financial Statements

News

Half Year 2025 Vivoryon Therapeutics NV Earnings Call Transcript

Half Year 2025 Vivoryon Therapeutics NV Earnings Call Transcript

12 hours ago - GuruFocus

Vivoryon Therapeutics NV (STU:05Y) Q3 2024 Earnings Call Highlights: Strategic Shifts and ...

Vivoryon Therapeutics NV (STU:05Y) Q3 2024 Earnings Call Highlights: Strategic Shifts and Financial Challenges

9 months ago - GuruFocus

Q3 2024 Vivoryon Therapeutics NV Earnings Call Transcript

Q3 2024 Vivoryon Therapeutics NV Earnings Call Transcript

9 months ago - GuruFocus